Elevance Q3 2026 Earnings: Most of the Guidance Raise Won't Recur

Elevance raised its 2026 guide by $2 a share on October 21, and by the end of the week at least nine brokers had raised their price targets. The figure I'd look at instead is the one Elevance grows from. Its earnings baseline, the 2026 number it promises to grow at least 12% from in 2027, rose $0.75, to at least $26.75. And 12% on $26.75 is about $30, which is roughly what Elevance earned in 2025.

The baseline, in the release's words, "excludes non-recurring net investment income and other non-operating items, as well as targeted one-time investments." So the gap between the $2 raise and the $0.75 is a net figure: one-off gains taken out, one-off spending added back, and a Q4 tax charge Elevance hasn't sized. It's still the company's own read of how much of the year recurs, and it's well under half of the headline.

Even without the $1.85, Elevance beat consensus by about 45 cents, so the operations did better than expected. They didn't do $2 better. And once you put the 2027 promise next to 2025, it's a recovery: at 12%, 2027 only gets Elevance back to where it was last year.

Split by segment, Q3 has two moving parts. Carelon, the pharmacy and care services arm, grew its operating gain 17% to about $908 million and widened its margin to 4.7% from 4.2%. Health Benefits, the insurance book, earned $436 million, down 27.5%, on a 1.0% margin. Q3 is the insurer's seasonal low, so Carelon out-earning it two to one is a Q3 fact. Over nine months the insurer still earned more, about $3.5 billion against Carelon's roughly $2.9 billion, but Carelon is the half that's growing.

Inside the insurer, the core line did get better. The benefit expense ratio fell 70 basis points to 90.6%, on better results in Medicare Advantage and the individual ACA business. What pulled reported profit down was a 90 basis point rise in the operating expense ratio, which Elevance put down partly to "targeted, one-time investments." The release doesn't split that spending by segment, so I can't say how much of the insurer's drop it explains.

The strongest objection is that I'm reading the wrong margin. Elevance's medical costs improved, and the spending that dragged down the segment's profit is the same one-time spending the baseline adds back. On that view the insurance book is already recovering on a recurring basis, and the reported 1.0% understates it. CFO Mark Kaye also said the baseline raise reflected third-quarter operating outperformance, and he expects "a modestly higher full-year operating margin" in the ACA business as claims develop favorably.

The second part is timing. Management called 2026 "the trough for our Medicaid margin," said the July rate updates "did provide greater support to the second half margins," and expects Medicare Advantage margins to improve in 2027 toward a 3% to 5% long-term range. Elevance has also guided low all year, raising the 2026 number three times from at least $25.50 in January. If Medicaid rates keep catching up and a smaller Medicare book is better priced, the insurer could carry a lot of 2027, and 12% would be a floor.

I think that's partly right, and it's why I've narrowed what I'm claiming. The insurer's medical costs are improving, and some of the reported margin drop will reverse. What I'm still saying is that the recurring improvement is $0.75 on Elevance's own measure, which already gives it credit for the one-time spending, and that the 2027 target gets earnings back to 2025. The recovery case also leans on state Medicaid rates and Medicare pricing that Elevance doesn't set. Kaye said "rates have certainly not fully caught up with the underlying costs," and that Elevance is "planning for incremental acuity pressure" from some of the changes.

UnitedHealth is where the bull case on Elevance is already true. Its reserve development flatters Q3 against the first half, but take it out and UnitedHealthcare's margin is still about half a point above last year's by my rough math, so its insurance book is repricing its way back on the reported numbers. Elevance's might be doing the same underneath, but it isn't showing in the segment yet. This is a two-company read until CVS and Humana report.

In my October note on Humana and the star rating that pays once I argued that what lasts in managed care is what keeps earning through a bad star year, and I counted Elevance's Blue Cross licences among those things. Q3 fits that. Elevance's regulatory lock-in and network effects are rated strong, and the members they protect stayed put: BlueCard, the network that serves other Blue plans' members in Elevance's states, grew 3.2%, and employer fee-based membership grew 1.9%, while Medicare Advantage shrank 15.5%. What the licence doesn't do is set the margin on the risk business. The bundling pillar, where Carelon would show up as a real Optum rival, is still rated weakened.

The refresh of Elevance's analysis that ships with this piece keeps the moat and the scenario targets where they were, rewrites the base case around the 12% target, keeps Carelon's revenue driver at decelerating (its revenue growth slowed from 7.9% to 6% to 5% this year even as its profit rose), and re-scores valuation at the current price. At a price near the base case, the stock needs the 12% to be met, and meeting it only gets earnings back to 2025. As CVS and Humana report, I'd read each one the same way: the baseline before the guide, and the segments before the total.